Frequency of lipid-lowering drug therapy after coronary and carotid operations for atherosclerosis

Southern Medical Journal

Volumn 93, Issue 4, 2000, Pages 424-426

  Roberts, Charles S ^a,b   Donovan, Kimberly D ^a   McCarthy, Paige J ^a   Keagy, Blair A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CB 7065 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CAROTID ENDARTERECTOMY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; RISK MANAGEMENT; SECONDARY PREVENTION;

EID: 0034107620     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200004000-00014     Document Type: Article

References (13)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015-3023
2. Pearson T, Rapaport E, Criqui M, et al: Optimal risk factor management in the patient after coronary revascularization: a statement for healthcare professionals from an American Heart Association writing group. Circulation 1994; 90:3125-3133
3. Kalan JM, Roberts WC: Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. Am Heart J 1990; 119:1164-1184
4. Mautner SL, Mautner GC, Hunsberger SA, et al: Comparison of composition of atherosclerotic plaques in saphenous veins used as aortocoronary bypass conduits with plaques in native coronary arteries in the same man. Am J Cardiol 1992; 70:1380-1387
5. The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336:153-162
6. Daida H, Yokoi H, Miyano H, et al: Relation of saphenous vein graft obstruction to serum cholesterol levels. J Am Coll Cardiol 1995; 25:193-197
7. Sacks FM, Pfeffer MA, Move LA, et al, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009
8. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357
9. He G-W, Acuff TE, Ryan WH, et al: Determinants of operative mortality in reoperative coronary artery bypass grafting. J Thorac Cardiovasc Surg 1995; 110:971-978
10. Moore WS, Kempczinski RF, Helson JJ, et al, for the ACAS Investigators: Recurrent carotid stenosis: results of the asymptomatic carotid atherosclerosis study. Stroke 1998; 29:2018-2031
11. Crouse JR III, Byington RP, Hoen HM, et al: Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157:1305-1310
12. O'Leary DH, Polak JF, Kronmal RA, et al: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340:14-22
13. Hebert PR, Gaziano JM, Chan KS, et al: Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997; 278:313-321